Is Eli Lilly's 16% Drop Over After 100 Days of Selling?

Eli Lilly Just Recovered From Its Worst Stretch in 100 Days. Is the Bottom In?

Eli Lilly and Company (LLY) has officially transitioned from a period of sustained selling pressure into a recovery phase as of May 1, 2026. After spending 106 days in a drawdown, the stock has stabilized within the yellow zone, signaling that the most aggressive phase of its recent decline may have plateaued. Our data shows that this specific type of recovery, where a stock halts its slide and begins to consolidate within an elevated risk tier, often precedes a period of heightened volatility before a full return to all-time highs.

Understanding the Current Drawdown Severity Score™

As of May 1, 2026, the Drawdown Severity Score™ for Eli Lilly stands at 3.1. This score places the stock in the "Elevated" or yellow zone, representing a -15.8% decline from its all-time high of $1109.94. While a 15.8% drop might seem standard for many growth stocks, it is significant for a company of Lilly’s market capitalization.

The current price of $934.31 follows a 106-day period of downward movement. This duration is notably longer than the company's historical average drawdown duration of 62 days. When a stock exceeds its average recovery time by more than 40 days, it indicates that the market is repricing the asset based on shifting fundamental expectations rather than a simple technical correction. Our Drawdown Severity Score™ helps quantify this shift by measuring the intensity of the selling relative to the stock's own historical volatility.

How Eli Lilly Compares to Recent Large-Cap Recoveries

The path Eli Lilly and Company (LLY) is currently taking mirrors several other high-profile recoveries we have tracked recently. When Apple (AAPL) and Microsoft (MSFT) faced similar 15% pullbacks earlier this year, they also lingered in the yellow zone for several weeks before making a definitive move back toward the green zone. The yellow zone is a transitionary period: it suggests that while the immediate "free fall" has stopped, the stock has not yet regained the momentum required to challenge its previous peaks.

Our data shows that stocks in the pharmaceutical sector typically spend more time in the yellow zone than technology stocks. This is often due to the binary nature of clinical trials and regulatory news. While a tech stock might bounce 5% on a single analyst upgrade, a company like Lilly often requires a specific fundamental catalyst, such as the earnings beat reported on May 1, 2026, to shift its Drawdown Severity Score™ back toward lower risk levels.

Historical Context: 228 Drawdown Events

To understand the current -15.8% drawdown, we must look at the 228 historical drawdown events we have recorded for Eli Lilly and Company (LLY). Historically, the stock's average maximum drawdown is only -5.4%. The current decline is nearly triple that average, which explains why the Drawdown Severity Score™ remains elevated despite the recent price stabilization.

In the company's extensive history, it has only dropped by 40% or more 4 times. These rare, severe events had an average duration of 1849 days to fully recover. It is important to note the small sample size for these extreme drops, but they serve as a reminder of the "worst-case" historical precedent. The current 106-day drawdown is far from those multi-year recovery periods, but it represents one of the more persistent pullbacks Lilly has faced in the last five years.

Earnings Momentum and the GLP-1 Catalyst

The primary driver behind the recent stabilization in the Drawdown Severity Score™ is the company’s first-quarter 2026 financial performance. According to PR Newswire, Lilly raised its full-year guidance and highlighted significant momentum for its new medicines. CNBC reported that the company "blew past" quarterly estimates, specifically citing skyrocketing sales for its GLP-1 drugs, Zepbound and Mounjaro.

Yahoo Finance noted that the stock soared following the earnings release as revenue grew 56% year-over-year. This surge in revenue, driven by what Investor's Business Daily described as "overwhelming demand" for its weight-loss and diabetes portfolio, provided the necessary support to stop the stock's slide at the -15.8% mark. Without this fundamental boost, our data suggests the stock could have easily slipped into the orange zone, which indicates a more severe technical breakdown.

The Road Back to the Green Zone

Despite the positive earnings news, Eli Lilly and Company (LLY) still has significant ground to cover. To reach its previous all-time high of $1109.94, the stock must climb approximately 18.8% from its current price of $934.31. In our framework, a stock typically returns to the "Green Zone" (Low Severity) once it recovers to within 5-7% of its peak.

We are currently monitoring the 3.1 Drawdown Severity Score™ to see if the post-earnings momentum can be sustained. Historically, when Lilly recovers from a yellow zone triggered by earnings, it tends to see a "cooling off" period where the stock trades sideways for 10 to 15 days before making its next leg up. Investors should watch the $1000 level closely: reclaiming that psychological round number would likely result in a significant improvement in the severity score.